Previous 10 | Next 10 |
2023-06-30 15:13:07 ET Shares of AC Immune (NASDAQ: ACIU) were up more than 54% for the week as of 2:30 p.m. on Friday, after being up by as much as 60.5%, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech company's stock closed la...
2023-06-28 08:18:51 ET AST SpaceMobile ( ASTS ) -30% on pricing upsized $59.4M equity offering. American Rebel Holdings ( AREB ) -27% . Eton Pharmaceuticals ( ETON ) -15% as FDA rejects methanol poisoning therapy . Centogene ( CNTG ) -12% ...
2023-06-27 13:14:58 ET Gainers: AC Immune ( ACIU ) +48% . Tivic Health Systems ( TIVC ) +47% . The Arena Group Holdings ( AREN ) +27% . Ispire Technology ( ISPR ) +21% . Enovix Corporation ( ENVX ) +20% . Advanced Health Inte...
2023-06-27 10:07:53 ET Gainers: Black Diamond Therapeutics ( BDTX ) +91% . Cara Therapeutics ( CARA ) +27% . Pharvaris ( PHVS ) +21% . AC Immune ( ACIU ) +11% . Immix Biopharma ( IMMX ) +6% . Losers: Adicet Bio ( ACET ...
2023-06-27 08:44:11 ET Swiss biotech AC Immune SA ( NASDAQ: ACIU ) added ~14% pre-market Tuesday after announcing that the FDA issued Fast Track designation for its anti-amyloid vaccine ACI-24.060 as a treatment for Alzheimer’s disease (AD). The FDA offers the Fast Tr...
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid- beta Active Immunotherapy , ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE study enrolling well and expanding to sites in USA with Investigational New Drug (IND) c...
2023-06-11 12:00:02 ET Driven by novel therapeutics from Biogen ( NASDAQ: BIIB )/ Eisai ( OTCPK:ESALF ) and Eli Lilly ( NYSE: LLY ), the Alzheimer’s disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said las...
2023-05-14 12:00:49 ET Leqembi, the new Alzheimer's therapy developed by Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESAIY ), could add $2B - $5B costs to Medicare annually, in the event of broader coverage, according to a recently published study. Early th...
2023-04-28 07:31:39 ET AC Immune press release ( NASDAQ: ACIU ): Q1 GAAP EPS of -CHF0.21. For further details see: AC Immune GAAP EPS of -CHF0.21
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer’s disease (AD) cohort in ABATE Phase 1b/2 trial; Further ABATE immunogenicity and safety...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...